Phase I dose-expansion findings tied biomarker analysis to clinical monitoring for AZD2811 in relapsed or refractory small-cell lung cancer (SCLC), researchers reported in a featured update. The work described how biomarker readouts tracked treatment efficacy signals across the study’s dose-escalation and expansion phases. The findings, led by Johnson, Fabbri, Ciardullo and colleagues, focus on using biomarker analysis to interpret response dynamics in a disease where objective response rates and durability often drive future trial design. For developers, the report highlights a practical strategy for incorporating translational endpoints into early oncology dosing studies to support later program decisions.